Additionally, the focus on HER2 subtypes and the intricate interplay with immunogenetic factors, as seen in the study by Erika J. Schneble et al (2013), highlights the need for a more nuanced understanding of the patient-specific factors influencing vaccine response.[11] The limited representation of certain subgroups in these trials necessitates further investigation to elucidate the vaccine’s efficacy in diverse breast cancer populations. The gene discussed is ERBB2; the disease is breast carcinoma.